WANTAI BIOLOGICAL(SH:603392) Zhong Guo Xin Wen Wang·2025-09-26 07:05Core Viewpoint - The launch of the domestic nine-valent HPV vaccine in Zhejiang Province marks a significant advancement in cervical cancer prevention for eligible women aged 9 to 45, offering a more accessible and affordable option compared to imported vaccines [1][3]. Group 1: Vaccine Launch and Pricing - The domestic nine-valent HPV vaccine is priced at 499 yuan per dose, approximately 40% lower than similar imported vaccines, enhancing accessibility for eligible women [1][3]. - The first dose of the vaccine was administered to a high school student during the launch event, indicating the commencement of the vaccination program in Zhejiang [3]. Group 2: Health Impact and Clinical Trials - Cervical cancer incidence is rising, particularly among younger women, making early vaccination crucial for effective protection against HPV and cervical cancer [3][4]. - Clinical trials show that the domestic nine-valent HPV vaccine provides a 100% protection rate against persistent infections of high-risk types for cervical cancer over 12 months, establishing a strong preventive measure [4]. Group 3: Community Support and Initiatives - WanTai Biologics announced a donation of 6,000 doses of the bivalent HPV vaccine to the Zhejiang Cancer Foundation to support public health initiatives, particularly for underserved populations [4]. - The Zhejiang Cancer Foundation has implemented various programs to assist cancer patients and promote early detection and treatment, reinforcing the importance of community health initiatives [5]. Group 4: Future Plans and Goals - The vaccination program for the domestic nine-valent HPV vaccine is set to expand across Zhejiang starting in October, aiming to significantly increase the HPV vaccination rate in the province [5]. - The initiative is expected to contribute to the broader goal of eliminating cervical cancer in China, aligning with global public health objectives [5].